Biovigilance and pharmacovigilance for haemophilia.
Weinstein
M
M
Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA.
Makris
M
M
Ludlam
C A
CA
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards*; D001779:Blood Coagulation Factors / Q000009:adverse effects*; D005060:Europe; D014943:Global Health; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D009656:North America; D011358:Product Surveillance, Postmarketing; D012308:Risk Management
D001779:Blood Coagulation Factors